Protocol Ledger

NCT02971501 · Phase II · ACTIVE NOT RECRUITING

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Interventional Phase II clinical trial protocol NCT02971501 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-06-27 Enrollment: 5 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT02971501
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)5 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT02971501
Protocol FieldVerified Registry Value
NCT IdentifierNCT02971501
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment5 participants (ACTUAL)
Registered Start Date2018-06-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI